dc.contributor.author | Brogan, Paul | |
dc.contributor.author | Lehane, Patricia B. | |
dc.contributor.author | Cooper, Jennifer | |
dc.contributor.author | Pordeli, Pooneh | |
dc.contributor.author | Kirchner, Petra | |
dc.contributor.author | Cleary, Gavin | |
dc.contributor.author | Rangaraj, Satyapal | |
dc.contributor.author | Melega, Simone | |
dc.contributor.author | Hersh, Aimee O. | |
dc.contributor.author | KASAPÇOPUR, ÖZGÜR | |
dc.contributor.author | Yeung, Rae S. M. | |
dc.contributor.author | Zeft, Andrew | |
dc.date.accessioned | 2022-07-04T15:52:26Z | |
dc.date.available | 2022-07-04T15:52:26Z | |
dc.identifier.citation | Melega S., Brogan P., Cleary G., Hersh A. O. , KASAPÇOPUR Ö., Rangaraj S., Yeung R. S. M. , Zeft A., Cooper J., Pordeli P., et al., "Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis", RHEUMATOLOGY AND THERAPY, 2022 | |
dc.identifier.issn | 2198-6576 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_c786c9d2-310a-49cf-ae78-4f5931fa663e | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/184637 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/c786c9d2-310a-49cf-ae78-4f5931fa663e/file | |
dc.identifier.uri | https://doi.org/10.1007/s40744-022-00433-0 | |
dc.description.abstract | Introduction The aim of this work was to assess the impact of prolonged low immunoglobulin (IgG or IgM) serum concentrations on the potential cumulative serious infection (SI) risk in pediatric patients following rituximab treatment for granulomatosis with polyangiitis or microscopic polyangiitis (GPA/MPA) in PePRS. Methods Patients aged >= 2 to = 4 months. Results A total of 25 patients were included, of whom 19 (76%) had GPA and six (24%) had MPA; 18 (72%) had newly diagnosed disease and seven (28%) had relapsing disease. All 25 patients completed the rituximab induction regimen; 24 completed >= 18 months of follow-up. At month 18, eighteen patients (72%) had prolonged low IgG; 19 (76%), prolonged low IgM; and 15 (60%), both. Seven patients (28%) had nine SIs; one occurred during or after prolonged low IgG only, two during or after prolonged low IgM only, and six during or after concurrent prolonged low IgG and IgM. No patients died or discontinued the study due to SI. All patients had complete and sustained peripheral B-cell depletion for >= 6 months. Conclusions The majority of pediatric patients who received rituximab for GPA/MPA with prolonged low immunoglobulin levels did not experience SIs. In patients with SIs, these events were manageable, and the number of SIs did not increase over time or with multiple rituximab treatments. These observations are consistent with the rituximab safety profile in adults with GPA/MPA. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | Rheumatology | |
dc.subject | Health Sciences | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ROMATOLOJİ | |
dc.title | Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis | |
dc.type | Makale | |
dc.relation.journal | RHEUMATOLOGY AND THERAPY | |
dc.contributor.department | F Hoffmann La Roche Ltd , , | |
dc.contributor.firstauthorID | 3401979 | |